RET and thyroid gland carcinoma: Following the LIBRETTO-001 trial, Selpercatinib was approved by the US FDA for the treatment of RET-fusion positive NSCLC, RET-mutant driven MTC, and other RET-fusion driven thyroid cancers refractory to radioactive iodine therapy.